Literature DB >> 22442280

Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study.

Palmiero Monteleone1, Fabiana Piscitelli, Pasquale Scognamiglio, Alessio Maria Monteleone, Benedetta Canestrelli, Vincenzo Di Marzo, Mario Maj.   

Abstract

BACKGROUND: Hedonic hunger refers to consumption of food just for pleasure and not to maintain energy homeostasis. In this condition, the subject eats also when not in a state of short-term energy depletion, and food is consumed uniquely because of its gustatory rewarding properties. The physiological mechanisms underlying this eating behavior are not deeply understood, but endogenous rewarding mediators like ghrelin and endocannabinoids are likely involved. OBJECTIVE AND
DESIGN: To explore the role of these substances in hedonic eating, we measured changes in their plasma levels in eight satiated healthy subjects after ad libitum consumption of highly palatable food as compared with the consumption of nonpalatable food in isoenergetic amounts with the same nutrient composition of the palatable food.
RESULTS: The consumption of food for pleasure was characterized by increased peripheral levels of both the peptide ghrelin and the endocannabinoid 2-arachidonoyl-glycerol. Levels of the other endocannabinoid anandamide and of anandamide-related mediators oleoylethanolamide and palmitoylethanolamide, instead, progressively decreased after the ingestion of both highly pleasurable and isoenergetic nonpleasurable food. A positive correlation was found between plasma 2-arachidonoyl glycerol and ghrelin during hedonic but not nonhedonic, eating.
CONCLUSIONS: The present preliminary findings suggest that when motivation to eat is generated by the availability of highly palatable food and not by food deprivation, a peripheral activation of two endogenous rewarding chemical signals is observed. Future research should confirm and extend our results to better understand the phenomenon of hedonic eating, which influences food intake and, ultimately, body mass.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22442280     DOI: 10.1210/jc.2011-3018

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  51 in total

1.  Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerol.

Authors:  E C Hanlon; E Tasali; R Leproult; K L Stuhr; E Doncheck; H de Wit; C J Hillard; E Van Cauter
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 2.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

Review 3.  New insights on the role of the endocannabinoid system in the regulation of energy balance.

Authors:  B Gatta-Cherifi; D Cota
Journal:  Int J Obes (Lond)       Date:  2015-09-16       Impact factor: 5.095

Review 4.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

5.  Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity.

Authors:  A M Monteleone; V Di Marzo; P Monteleone; R Dalle Grave; T Aveta; M El Ghoch; F Piscitelli; U Volpe; S Calugi; M Maj
Journal:  Eur J Nutr       Date:  2016-01-12       Impact factor: 5.614

6.  Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity.

Authors:  Donovan A Argueta; Nicholas V DiPatrizio
Journal:  Physiol Behav       Date:  2017-01-05

Review 7.  Hormonal and neural mechanisms of food reward, eating behaviour and obesity.

Authors:  Susan Murray; Alastair Tulloch; Mark S Gold; Nicole M Avena
Journal:  Nat Rev Endocrinol       Date:  2014-06-24       Impact factor: 43.330

8.  Circulating Endocannabinoids and Mortality in Hemodialysis Patients.

Authors:  Hamid Moradi; Christina Park; Elani Streja; Donovan A Argueta; Nicholas V DiPatrizio; Amy S You; Connie M Rhee; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Daniele Piomelli
Journal:  Am J Nephrol       Date:  2020-01-14       Impact factor: 3.754

9.  Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice.

Authors:  Carmelo Quarta; Daniela Cota
Journal:  Int J Obes (Lond)       Date:  2020-04-21       Impact factor: 5.095

10.  Associations of ghrelin with eating behaviors, stress, metabolic factors, and telomere length among overweight and obese women: preliminary evidence of attenuated ghrelin effects in obesity?

Authors:  Julia Buss; Peter J Havel; Elissa Epel; Jue Lin; Elizabeth Blackburn; Jennifer Daubenmier
Journal:  Appetite       Date:  2014-01-22       Impact factor: 3.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.